Novo Nordisk A/S - share repurchase programme
Key takeaways
- Novo Nordisk is using its cash flow to buy back up to DKK 15 billion of B shares, reducing share count and supporting the stock price.
- DKK 15 billion total buyback cap
- DKK 11.2 billion allocated for 6 May 2026–1 Feb 2027
- 35,379,179 shares repurchased
What happened
Novo Nordisk announced it has begun a share repurchase programme that can buy up to DKK 15 billion of its B shares over a 12‑month period starting 4 February 2026. The programme, launched on 6 May 2026, allows the company to repurchase B shares for up to DKK 11.2 billion between 6 May 2026 and 1 February 2027. As of 25 September 2026, Novo has bought 35,379,179 B shares at an average price of DKK 280.95, spending DKK 9.94 billion. The company now holds 49,419,876 treasury B shares,…
Why it matters
The repurchase programme signals Novo’s confidence in its long‑term value and provides a mechanism to return capital to shareholders. By buying back shares, the company reduces the number of shares outstanding, which can lift earnings per share and support the share price. The programme also demonstrates that Novo…
Short-term and longer-term
Short-term. Over the next few weeks, watch for any new repurchase transactions that could signal the pace of the programme.
Longer-term. For investors looking ahead, the buyback demonstrates Novo’s strong cash flow and willingness to return capital, which could support the stock’s valuation over the next year.